WO2006050794A1 - Use of acetyl l-carnitine in combination with propionyl l-carnitine and sildenafil for the treatment of erectile dysfunction - Google Patents Use of acetyl l-carnitine in combination with propionyl l-carnitine and sildenafil for the treatment of erectile dysfunction Download PDF Info Publication number WO2006050794A1 WO2006050794A1 PCT/EP2005/011238 EP2005011238W WO2006050794A1 WO 2006050794 A1 WO2006050794 A1 WO 2006050794A1 EP 2005011238 W EP2005011238 W EP 2005011238W WO 2006050794 A1 WO2006050794 A1 WO 2006050794A1 Authority WO WIPO (PCT) Prior art keywords carnitine acid treatment erectile dysfunction acetyl Prior art date Legal status (The legal status is an assumption and is not a legal conclusion
Shipping details are handled during the order process
The benefits of GLP-1 RAs are derived from their pleiotropic effects, which include glucose-dependent insulin secretion, suppressed glucagon secretion, and reduced appetite
1 Introduction Rhabdomyolysis is characterized by the breakdown of skeletal muscle fibers, resulting in the release of intracellular contents such as myoglobin and creatine kinase (CK) into the bloodstream ( 2 Case presentation A 66-year-old woman presented to the emergency department with profound weakness, nausea, and repeated vomiting, 1 day after receiving her first subcutaneous dose of tirzepatide (Mounjaro) at a supratherapeutic dose of 15 mg (recommended starting dose: 2.5 mg)
Full Certificates of Analysis (CoA) are available upon request to ensure the highest purity standards
Test sessions were conducted on the first, third, and eighth injection days (termed injection 1, injection 3, and injection 8, respectively) and on post-treatment days 1 and 3 (see Fig
